Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $73.33 billion. The enterprise value is $57.75 billion.
| Market Cap | 73.33B |
| Enterprise Value | 57.75B |
Important Dates
The next confirmed earnings date is Tuesday, February 4, 2025, before market open.
| Earnings Date | Feb 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
REGN has 107.59 million shares outstanding. The number of shares has increased by 1.16% in one year.
| Current Share Class | 105.77M |
| Shares Outstanding | 107.59M |
| Shares Change (YoY) | +1.16% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 3.59% |
| Owned by Institutions (%) | 88.24% |
| Float | 103.56M |
Valuation Ratios
The trailing PE ratio is 16.86 and the forward PE ratio is 14.84. REGN's PEG ratio is 0.93.
| PE Ratio | 16.86 |
| Forward PE | 14.84 |
| PS Ratio | 5.30 |
| Forward PS | 4.79 |
| PB Ratio | 2.51 |
| P/TBV Ratio | 2.60 |
| P/FCF Ratio | 21.32 |
| P/OCF Ratio | 17.26 |
| PEG Ratio | 0.93 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.56, with an EV/FCF ratio of 16.79.
| EV / Earnings | 12.41 |
| EV / Sales | 4.17 |
| EV / EBITDA | 12.56 |
| EV / EBIT | 13.99 |
| EV / FCF | 16.79 |
Financial Position
The company has a current ratio of 5.28, with a Debt / Equity ratio of 0.09.
| Current Ratio | 5.28 |
| Quick Ratio | 4.34 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.59 |
| Debt / FCF | 0.79 |
| Interest Coverage | 65.53 |
Financial Efficiency
Return on equity (ROE) is 17.17% and return on invested capital (ROIC) is 8.65%.
| Return on Equity (ROE) | 17.17% |
| Return on Assets (ROA) | 7.41% |
| Return on Capital (ROIC) | 8.65% |
| Revenue Per Employee | $1.03M |
| Profits Per Employee | $346,059 |
| Employee Count | 13,450 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.44 |
Taxes
In the past 12 months, REGN has paid $314.90 million in taxes.
| Income Tax | 314.90M |
| Effective Tax Rate | 6.34% |
Stock Price Statistics
The stock price has decreased by -27.28% in the last 52 weeks. The beta is 0.09, so REGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -27.28% |
| 50-Day Moving Average | 746.26 |
| 200-Day Moving Average | 959.39 |
| Relative Strength Index (RSI) | 36.28 |
| Average Volume (20 Days) | 856,997 |
Short Selling Information
The latest short interest is 2.10 million, so 1.95% of the outstanding shares have been sold short.
| Short Interest | 2.10M |
| Short Previous Month | 1.88M |
| Short % of Shares Out | 1.95% |
| Short % of Float | 2.02% |
| Short Ratio (days to cover) | 2.44 |
Income Statement
In the last 12 months, REGN had revenue of $13.85 billion and earned $4.65 billion in profits. Earnings per share was $40.43.
| Revenue | 13.85B |
| Gross Profit | 7.03B |
| Operating Income | 4.13B |
| Pretax Income | 4.59B |
| Net Income | 4.65B |
| EBITDA | 4.60B |
| EBIT | 4.13B |
| Earnings Per Share (EPS) | $40.43 |
Balance Sheet
The company has $9.80 billion in cash and $2.70 billion in debt, giving a net cash position of $15.58 billion or $144.84 per share.
| Cash & Cash Equivalents | 9.80B |
| Total Debt | 2.70B |
| Net Cash | 15.58B |
| Net Cash Per Share | $144.84 |
| Equity (Book Value) | 29.33B |
| Book Value Per Share | 272.04 |
| Working Capital | 15.67B |
Cash Flow
In the last 12 months, operating cash flow was $4.25 billion and capital expenditures -$807.70 million, giving a free cash flow of $3.44 billion.
| Operating Cash Flow | 4.25B |
| Capital Expenditures | -807.70M |
| Free Cash Flow | 3.44B |
| FCF Per Share | $31.97 |
Margins
Gross margin is 50.75%, with operating and profit margins of 29.81% and 33.61%.
| Gross Margin | 50.75% |
| Operating Margin | 29.81% |
| Pretax Margin | 35.89% |
| Profit Margin | 33.61% |
| EBITDA Margin | 33.21% |
| EBIT Margin | 29.81% |
| FCF Margin | 24.84% |
Dividends & Yields
REGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.16% |
| Shareholder Yield | -1.16% |
| Earnings Yield | 6.35% |
| FCF Yield | 4.69% |
Analyst Forecast
The average price target for REGN is $1,024.28, which is 50.28% higher than the current price. The consensus rating is "Buy".
| Price Target | $1,024.28 |
| Price Target Difference | 50.28% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (5Y) | 7.43% |
| EPS Growth Forecast (5Y) | 13.78% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 10.04 and a Piotroski F-Score of 4.
| Altman Z-Score | 10.04 |
| Piotroski F-Score | 4 |